Neovacs to Expand Clinical Testing of its TNF-a Kinoid Lead Product Candidate
Want to listen to this article for FREE?
Complete the form below to unlock access to ALL audio articles.
Read time: Less than a minute
Neovacs has announced that subject to regulatory consent, it plans to initiate a Phase II study of its TNF-a Kinoid later this year in rheumatoid arthritis patients who have failed treatment with at least one TNF-a inhibitor.
The decision to proceed with the trial was based on an initial review of encouraging data from the company’s Phase I/II study in Crohn’s disease.
The decision to proceed with the trial was based on an initial review of encouraging data from the company’s Phase I/II study in Crohn’s disease.
